Vendor, Atlanta, GA
Metaclipse Therapeutics Corp.
UEI MU6JZBDZR8X1, CAGE 6BYQ1
1 award and $299,984 obligated between September 4, 2025 and August 11, 2026, 100% under full and open competition, against 55.0 offers on average where reported.
Industries
NAICS on the awards, by dollars.
| Research and Development in NanotechnologyNAICS 541713 | $299,984 |
How it wins
Awards by competition, set-aside and type.
| Full and Open Competition After Exclusion of Sources | 1 |
| Small Business Set Aside - Total | 1 |
| Definitive Contract | 1 |
Hear when Metaclipse Therapeutics Corp. wins an award and when a contract it holds is about to end.Follow it
Contracts ending soon
Contracts Metaclipse Therapeutics Corp. holds whose performance ends in the next 19 months, by published end date. Each one is a recompete to prepare for.
- Ending
- 1
- Obligated so far
- $299,984
- Soonest
- June 4, 2027
The 1 contract, the office behind each one and the dates are in the workspace. See them
Competes with
Vendors selling research and development in nanotechnology to National Institutes of Health, by dollars.
| The Emmes Company, LLCRockville, MD | $236,867,851 |
| Angstrom Research Inc.Lunenburg, MA | $353,102 |
| Medicines and Healthcare Products Regulatory AgencyLondon | $55,961 |
| Humanetics CorporationEdina, MN | $0 |
| Tecan Genomics, Inc.Redwood City, CA | -$55,763 |
Awards
Every award in the window, by dollars obligated.
| Contract | Awarding office | Described as | Obligated |
|---|---|---|---|
| 75N91025C00038Definitive Contract, September 4, 2025, Full and Open Competition After Exclusion of Sources, 55 offers | NIH NCINational Institutes of Health | SBIR Concept Award for Development of Therapeutic or Preventative Technologies for Treatment or Prevention of Pediatric Cancers And/Or Rare NAICS 541713, PSC AN12 | $299,984 |
- Places of performance
- Georgia
- Product and service codes
- AN12 Health R&D Services; Health Care Services; Applied Research
- Transactions
- 2 across 1 awards